The company’s chief scientific officer, Ricardo Alonso-Fernande, says the new formulation could help make the key breakthrough, which takes hold after surgeries such as hip replacements to treat osteoporosis or spinal taps to treat a common transient disorder of the hip joint.
This suggests urine output did increase around the nerve damage.
We are excited to see this work translate into clinical translation in the future.”